Compounded vs Brand-Name GLP-1 Medications: Semaglutide, Tirzepatide, and What Actually Differs in 2026

What is the difference between compounded and brand-name GLP-1 medications?

Brand-name GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved, clinically trialed, and manufactured under standardized FDA-inspected conditions. Compounded GLP-1 medications are prepared by US-licensed compounding pharmacies under individual prescriptions from licensed providers. They contain the same active ingredient but are not FDA-approved and have not been independently evaluated in clinical trials. The practical result is a drug with the same molecular target at substantially lower cost, but with different regulatory status and different quality-control assumptions.

That distinction — same active ingredient, different regulatory status — sits at the center of every decision a patient makes between the two. Understanding what each difference means, rather than dismissing it, is what this guide is for.

Quick comparison: compounded vs brand-name GLP-1 medications

The table below summarizes the differences at a glance. Each factor is expanded in the sections that follow.

Is compounded semaglutide FDA approved?

No. Compounded semaglutide is not FDA-approved. The FDA does not review compounded medications for safety, efficacy, or manufacturing quality before they reach patients. This is the single most important fact patients should understand before starting compounded GLP-1 treatment.

FDA approval is a specific process that involves large-scale clinical trials, manufacturing inspections, and post-market surveillance. Only three semaglutide products have completed that process: Ozempic (approved for type 2 diabetes in 2017), Wegovy (approved for chronic weight management in 2021), and Rybelsus (oral semaglutide, approved for type 2 diabetes in 2019). Each is manufactured by Novo Nordisk.

Compounded semaglutide is prepared by compounding pharmacies using pharmaceutical-grade semaglutide active pharmaceutical ingredient sourced from FDA-registered suppliers. The active ingredient itself is the same molecule as the one in Ozempic and Wegovy when properly sourced. What differs is the final product — concentration, excipients, sterility, and packaging are determined by the compounding pharmacy rather than by Novo Nordisk.

Because compounded semaglutide has not been independently trialed, efficacy claims rely on the clinical data for the FDA-approved products. That data is strong — the STEP 1 trial demonstrated 14.9% mean weight loss over 68 weeks at the 2.4mg dose. However, extrapolating those results to a compounded version assumes the active ingredient is correctly dosed and absorbed, which depends on the compounding pharmacy's quality controls. Individual results vary.

Is compounded tirzepatide FDA approved?

No. Compounded tirzepatide is not FDA-approved. The only FDA-approved tirzepatide products are Mounjaro (for type 2 diabetes, approved in 2022) and Zepbound (for chronic weight management, approved in 2023). Both are manufactured by Eli Lilly.

As with semaglutide, compounded tirzepatide is prepared by compounding pharmacies using tirzepatide active ingredient sourced from FDA-registered suppliers. The active molecule is the same. The final product is not FDA-reviewed and is not therapeutically equivalent to Mounjaro or Zepbound.

The efficacy data for tirzepatide comes from the SURMOUNT trial program, which studied only the FDA-approved formulation. SURMOUNT-1 demonstrated weight loss of 22.5% over 72 weeks at the 15mg dose — the highest average weight loss observed in any anti-obesity medication trial to date. Compounded tirzepatide has not been evaluated in an equivalent trial.

Do compounded GLP-1 medications work as well as brand-name versions?

The honest answer is that there is no head-to-head clinical trial data comparing compounded and brand-name GLP-1 medications. What patients and providers have to work with is mechanistic reasoning — if the compounded product contains the correct dose of the correct molecule, it should produce similar clinical effects — combined with real-world observational data from patients using both.

The mechanistic case is strong. Semaglutide is semaglutide. The GLP-1 receptor does not know whether the molecule bound to it came from Novo Nordisk or a compounding pharmacy. The same reasoning applies to tirzepatide and the combined GLP-1/GIP receptor activation.

The caveats are also real. First, dose accuracy in compounded vials depends on the pharmacy's compounding process and on patient injection technique. A 10% under-dose can meaningfully reduce efficacy. Second, some early-generation compounded products used semaglutide salt forms (sodium or acetate) rather than semaglutide base. The FDA has flagged these salt forms as having different molecular weights and potentially different absorption profiles than the base form used in Ozempic and Wegovy. Reputable compounding pharmacies now use the base form exclusively. Third, inactive ingredients — stabilizers, preservatives, pH buffers — can vary between formulations and may affect tolerability, though there is no evidence they affect efficacy.

In published patient surveys and provider reports, compounded semaglutide and tirzepatide appear to produce clinical outcomes broadly similar to brand-name versions when properly sourced and dosed. This is consistent with the mechanistic expectation but is not the same as rigorous trial data.

How much cheaper is compounded GLP-1 vs brand-name?

Cost is the single factor that drives most patients to consider compounded GLP-1 medications. The gap is substantial, especially for patients without insurance coverage for weight management medications.

Brand-name monthly costs without insurance (as of April 2026):

• Wegovy (semaglutide 2.4mg for weight management): approximately $1,350/month list price; $499/month through NovoCare's self-pay program for eligible patients
• Ozempic (semaglutide for type 2 diabetes, prescribed off-label for weight loss): $900 to $1,350/month
• Zepbound (tirzepatide for weight management): approximately $1,060/month list price; $299 to $449/month through LillyDirect self-pay vials
• Mounjaro (tirzepatide for type 2 diabetes): $1,060 to $1,200/month

Compounded GLP-1 pricing and what it includes

Compounded GLP-1 pricing through licensed telehealth providers generally ranges from $120 to $350 per month, depending on the medication, the provider's business model, and what is included in the monthly fee.

Compounded semaglutide through telehealth typically runs $120 to $250 per month. Cora Health's Essential Plan starts at $120 per month on a 6-month plan and includes provider consultation, personalized treatment plan, compounded semaglutide, US-licensed pharmacy fulfillment from VialsRx, free expedited shipping, and ongoing provider monitoring — no separate consultation or subscription fees.

Compounded tirzepatide through telehealth typically runs $199 to $350 per month. Cora Health's Premium Plan starts at $199 per month on a 3-month plan and includes the same components as the Essential Plan plus priority support.

When comparing compounded GLP-1 prices across providers, patients should ensure the quoted monthly price is all-inclusive. Some providers advertise low medication prices but charge separately for the provider consultation, monthly check-ins, or prescription renewals, which can push the effective monthly cost 30 to 50% higher than the headline number.

Safety and quality: what actually differs

The safety conversation around compounded GLP-1 medications is less about the molecule and more about the manufacturing process. Brand-name semaglutide and tirzepatide are produced under FDA Good Manufacturing Practice (GMP) standards with validated batch testing, sterility assurance, and post-market surveillance. Compounded versions rely on the specific compounding pharmacy's standards.

A properly operated 503A compounding pharmacy follows USP (United States Pharmacopeia) standards — USP 795 for non-sterile compounding and USP 797 for sterile compounding, which is the relevant standard for injectable GLP-1 medications. Reputable pharmacies source pharmaceutical-grade active ingredients from FDA-registered suppliers, test finished products for potency, sterility, and endotoxins, and maintain detailed compounding records. State boards of pharmacy inspect 503A facilities. The FDA also exercises enforcement authority and has issued multiple warning letters to compounding facilities that fall short.

Where patients run into trouble is at pharmacies that do not follow these standards. The FDA has documented cases of compounded GLP-1 products with under-dosing, over-dosing, contamination, incorrect salt forms, and outright fraud. As of mid-2025, the FDA had received hundreds of adverse event reports related to compounded GLP-1 medications, many involving dosing errors.

The single most important question a patient can ask before starting compounded GLP-1 treatment is: which pharmacy will compound my medication, and what are its quality standards? A provider that cannot answer this, or that declines to name its pharmacy, is a red flag. Cora Health publicly names its pharmacy partner (VialsRx, a US-licensed 503A compounding pharmacy) and provides access to its credentialing information on request.

Legal status of compounded GLP-1 medications in 2026

The regulatory landscape for compounded GLP-1 medications has shifted significantly over the past two years. During the official FDA-declared shortages of semaglutide (2022 to February 2025) and tirzepatide (2022 to late 2024), compounding pharmacies had broad authority to prepare copies of the branded products. When the FDA declared those shortages resolved, that authority narrowed.

As of April 2026, compounded semaglutide and tirzepatide remain legal under specific conditions. A licensed prescriber must write a patient-specific prescription based on a documented clinical need that the commercially available FDA-approved product cannot meet — such as a documented allergy to an inactive ingredient, a documented need for a different dose strength or delivery format, or a documented clinical necessity for a personalized formulation. The compounding pharmacy must be properly licensed (503A state-licensed or 503B FDA-registered) and must meet applicable quality standards.

What is not legal is bulk production of compounded GLP-1 medications as a substitute for the branded product in the absence of a documented individual clinical need. The FDA has issued multiple warning letters, and in some cases initiated enforcement actions, against compounding operations that produced compounded GLP-1 medications without valid patient-specific prescriptions or outside the bounds of 503A and 503B exemptions.

The legal picture continues to evolve. Court rulings, FDA enforcement decisions, and state-level pharmacy board actions are ongoing. Patients choosing compounded GLP-1 medications in 2026 should work with providers who stay current on regulatory developments and who can demonstrate the legal basis for the compounded prescription they write.

Who should choose compounded GLP-1 medications?

Compounded GLP-1 medications may be a reasonable option for patients who meet specific criteria.

• Patients without insurance coverage for GLP-1 medications for weight management — the cost gap is too large to ignore for most self-pay patients
• Patients whose insurance plans exclude GLP-1 medications for weight loss, or require prior authorization processes that can take months
• Patients with a documented clinical need the FDA-approved product cannot meet — such as an inactive-ingredient allergy or a required dose format not available in the branded product
• Patients willing to work with a licensed provider and a verifiable compounding pharmacy that can name its quality standards

Who should choose brand-name GLP-1 medications?

Brand-name semaglutide or tirzepatide may be the better choice for patients who meet the following criteria.

• Patients with commercial insurance that covers Wegovy or Zepbound for weight management with a reasonable copay
• Patients with Medicare coverage for GLP-1 medications — the Medicare GLP-1 Bridge program began July 1, 2026 and covers eligible beneficiaries for $50/month
• Patients who prefer the convenience of pre-filled auto-injector pens over vials and syringes
• Patients who place a high value on FDA-reviewed manufacturing and post-market surveillance
• Patients with complex medical histories where the standardized formulation reduces variability in clinical decision-making

Frequently asked questions

Common questions about compounded vs brand-name GLP-1 medications.

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy, but it is not the same product. Ozempic is an FDA-approved finished drug manufactured by Novo Nordisk under FDA-inspected conditions. Compounded semaglutide is prepared by a compounding pharmacy from pharmaceutical-grade semaglutide active ingredient. It is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Ozempic or Wegovy.

Will compounded semaglutide produce the same weight loss as Wegovy?

Clinical trial data for semaglutide comes from studies of Wegovy (STEP 1: 14.9% mean weight loss at 2.4mg over 68 weeks). Compounded semaglutide has not been independently trialed. Mechanistically, the same active ingredient at the same dose should produce the same clinical effect, provided the compounded product is correctly dosed. Real-world reports suggest outcomes are broadly similar when the compounded product is sourced from a reputable pharmacy, but this is not a substitute for rigorous clinical evidence. Individual results vary.

Is compounded tirzepatide legal?

As of April 2026, compounded tirzepatide is legal when a licensed prescriber writes a patient-specific prescription based on a documented clinical need, and the compounding pharmacy is properly licensed (503A state-licensed or 503B FDA-registered). Bulk production as a generic substitute for Zepbound or Mounjaro without a documented individual clinical need falls outside the legal exemptions for compounding. The regulatory landscape continues to evolve.

Why is compounded semaglutide so much cheaper than Ozempic?

Brand-name GLP-1 medications are priced to recover the costs of clinical development, FDA approval, marketing, manufacturing at scale, and ongoing post-market studies. Novo Nordisk invested billions of dollars in the STEP, SUSTAIN, and SELECT trial programs for semaglutide. Compounded versions bypass these costs because the compounding pharmacy is not developing a new drug — it is preparing a specific dose of an already-characterized active ingredient under a valid prescription. This regulatory and economic structure makes compounded versions substantially less expensive. The tradeoff is that compounded versions lack the regulatory assurances that come with FDA approval.

Can I switch from compounded to brand-name or vice versa?

Yes, with appropriate provider oversight. Dose equivalence between compounded and brand-name products is generally straightforward when both use the same semaglutide base at the same dose, but the specific titration plan depends on your current dose, tolerance, and clinical picture. Discuss any switch with your provider before making the change — abrupt dose changes can increase side effects.

Where can I get compounded GLP-1 medications online?

Compounded semaglutide and tirzepatide are available through licensed telehealth providers that partner with US-licensed compounding pharmacies. When evaluating providers, look for board-certified physicians who conduct individual medical evaluations, a named and verifiable compounding pharmacy partner, LegitScript certification, transparent all-inclusive pricing, and a process that does not guarantee prescriptions before medical review. Cora Health provides compounded semaglutide ($120/month on a 6-month plan) and compounded tirzepatide ($199/month on a 3-month plan) through board-certified providers at Wasef Health, PC and US-licensed 503A pharmacy VialsRx. The service is available in all 50 US states.